, Les cancers en France en 2015

R. Duschinsky, E. Pleven, and C. Heidelberger, THE SYNTHESIS OF, vol.5

, FLUOROPYRIMIDINES, vol.79, issue.16, pp.4559-4560, 1957.

, WHO Model List of Essentiel Medecines 20th Edition.pdf

, Résumé des caractéristiques du produit -FLUOROURACILE PFIZER 50 mg/ml, solution à diluer pour perfusion -Base de données publique des médicaments

H. A. Ingraham, B. Y. Tseng, and M. Goulian, Nucleotide levels and incorporation of 5-fluorouracil and uracil into DNA of cells treated with 5-fluorodeoxyuridine, Mol. Pharmacol, vol.21, issue.1, pp.211-216, 1982.

J. Ciccolini, Transmission of apoptosis in human colorectal tumor cells exposed to capecitabine, Xeloda, is mediated via Fas, Mol. Cancer Ther, vol.1, issue.11, pp.923-927, 2002.

M. Barrat-petit, C. Naulin-ifi, P. Mahler, and G. Milano, Pathol. Biol, vol.53, issue.5, pp.261-264, 2005.

Z. Karjoo, X. Chen, and A. Hatefi, Progress and problems with the use of suicide genes for targeted cancer therapy, Adv. Drug Deliv. Rev, vol.99, pp.113-128, 2016.

A. T. Nies, T. Magdy, M. Schwab, and U. M. Zanger, Role of ABC transporters in fluoropyrimidine-based chemotherapy response, Adv. Cancer Res, vol.125, pp.217-243, 2015.

M. Tsalic, G. Bar-sela, A. Beny, B. Visel, and N. Haim, Severe toxicity related to the 5-fluorouracil/leucovorin combination (the Mayo Clinic regimen): a prospective study in colorectal cancer patients, Am. J. Clin. Oncol, vol.26, issue.1, pp.103-106, 2003.

J. Latchman, A. Guastella, and C. Tofthagen, 5-Fluorouracil toxicity and dihydropyrimidine dehydrogenase enzyme: implications for practice, Clin J Oncol Nurs, vol.18, issue.5, pp.581-585, 2014.

P. Alter, M. Herzum, M. Soufi, J. R. Schaefer, and B. Maisch, Cardiotoxicity of 5-fluorouracil, Cardiovasc Hematol Agents Med Chem, vol.4, issue.1, pp.1-5, 2006.

M. F. Sorrentino, J. Kim, A. E. Foderaro, and A. G. Truesdell, 5-fluorouracil induced cardiotoxicity: review of the literature, Cardiol J, vol.19, issue.5, pp.453-458, 2012.

A. Polk, M. Vaage-nilsen, K. Vistisen, and D. L. Nielsen, Cardiotoxicity in cancer patients treated with 5-fluorouracil or capecitabine: a systematic review of incidence, manifestations and predisposing factors, Cancer Treat. Rev, vol.39, issue.8, pp.974-984, 2013.

K. A. Kwon, A case of 5-fluorouracil induced encephalopathy, Cancer Res Treat, vol.42, issue.2, pp.118-120, 2010.

H. J. Yi, K. S. Hong, N. Moon, S. S. Chung, R. Lee et al., Acute hyperammonemic encephalopathy after 5-fluorouracil based chemotherapy, Ann Surg Treat Res, vol.90, issue.3, pp.179-182, 2016.

W. Y. Cheung, R. A. Fralick, and S. Cheng, The confused cancer patient: a case of 5-fluorouracil-induced encephalopathy, Curr Oncol, vol.15, issue.5, pp.234-236, 2008.

B. F. Werbrouck, W. J. Pauwels, J. L. De, and . Bleecker, A case of 5-fluorouracilinduced peripheral neuropathy, Clin Toxicol (Phila), vol.46, issue.3, pp.264-266, 2008.

F. Desmoulin, V. Gilard, M. Malet-martino, and R. Martino, Metabolism of capecitabine, an oral fluorouracil prodrug: (19)F NMR studies in animal models and human urine, Drug Metab. Dispos, vol.30, issue.11, pp.1221-1229, 2002.

S. W. Lam, H. J. Guchelaar, and E. Boven, Résumé des caractéristiques du produit -CAPECITABINE MYLAN 500 mg, comprimé pelliculé -Base de données publique des médicaments, Cancer Treat. Rev, vol.50, pp.9-22, 2016.

, Prescribing Information -Vistogard.pdf

D. J. Cada, U. Mbogu, R. J. Bindler, and D. E. Baker, Uridine Triacetate, Hosp Pharm, vol.51, issue.6, pp.484-488, 2016.

A. Gnoni, Pharmacokinetic and metabolism determinants of fluoropyrimidines and oxaliplatin activity in treatment of colorectal patients, Curr. Drug Metab, vol.12, issue.10, pp.918-931, 2011.

A. Lee, H. Ezzeldin, J. Fourie, and R. Diasio, Dihydropyrimidine dehydrogenase deficiency: impact of pharmacogenetics on 5-fluorouracil therapy, Clin Adv Hematol Oncol, vol.2, issue.8, pp.527-532, 2004.

L. K. Mattison, R. Soong, and R. B. Diasio, Implications of dihydropyrimidine dehydrogenase on 5-fluorouracil pharmacogenetics and pharmacogenomics, Pharmacogenomics, vol.3, issue.4, pp.485-492, 2002.

A. B. Van-kuilenburg, Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil, Eur. J. Cancer, vol.40, issue.7, pp.939-950, 2004.

G. Bocci, A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity, Clin. Pharmacol. Ther, vol.80, issue.4, pp.384-395, 2006.

B. E. Harris, R. Song, S. J. Soong, and R. B. Diasio, Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion, Cancer Res, vol.50, issue.1, pp.197-201, 1990.

H. Jiang, J. Lu, and J. Ji, Circadian rhythm of dihydrouracil/uracil ratios in biological fluids: a potential biomarker for dihydropyrimidine dehydrogenase levels, Br. J. Pharmacol, vol.141, issue.4, pp.616-623, 2004.

F. N. Naguib, S. J. Soong, and M. H. El-kouni, Circadian rhythm of orotate phosphoribosyltransferase, pyrimidine nucleoside phosphorylases and dihydrouracil dehydrogenase in mouse liver. Possible relevance to chemotherapy with 5-fluoropyrimidines, Biochem. Pharmacol, vol.45, issue.3, pp.667-673, 1993.

R. Zhang, Z. Lu, T. Liu, S. J. Soong, and R. B. Diasio, Relationship between circadian-dependent toxicity of 5-fluorodeoxyuridine and circadian rhythms of pyrimidine enzymes: possible relevance to fluoropyrimidine chemotherapy, Cancer Res, vol.53, issue.12, pp.2816-2822, 1993.

B. A. Jacobs, Pronounced between-subject and circadian variability in thymidylate synthase and dihydropyrimidine dehydrogenase enzyme activity in human volunteers, Br J Clin Pharmacol, vol.82, issue.3, pp.706-716, 2016.

K. Abolmaali, Circadian variation in intestinal dihydropyrimidine dehydrogenase (DPD) expression: a potential mechanism for benefits of 5FU chronochemotherapy, Surgery, vol.146, issue.2, pp.269-273, 2009.

M. Boisdron-celle, A. Morel, and E. Gamelin, Ann. Biol. Clin, vol.68, issue.1, pp.27-32, 2010.

X. Liu, M. Zhuang, Z. Wang, and R. M. Huber, Correlation between dihydropyrimidine dehydrogenase and efficacy and toxicity of fluoropyrimidine drugs, Eur Rev Med Pharmacol Sci, vol.18, issue.18, pp.2772-2776, 2014.

C. G. Yang, DPD-based adaptive dosing of 5-FU in patients with head and neck cancer: impact on treatment efficacy and toxicity, Cancer Chemother. Pharmacol, vol.67, issue.1, pp.49-56, 2011.

M. Launay, Beating the odds: efficacy and toxicity of dihydropyrimidine dehydrogenase-driven adaptive dosing of 5-FU in patients with digestive cancer, Br J Clin Pharmacol, vol.81, issue.1, pp.124-130, 2016.

, Question n°2878 -Assemblée nationale, p.13, 2019.

, Question n°4942 -Assemblée nationale, p.13, 2019.

, Question n°9017 -Assemblée nationale, p.13, 2019.

, Question n°9862 -Assemblée nationale, p.13, 2019.

, Prévention des effets indésirables graves liés à un déficit en dihydropyrimidine déshydrogénase (DPD) lors de traitement par fluoropyrimidines (5-fluorouracile et capécitabine) -Point d, ANSM, vol.28, p.2018

, Agence nationale de sécurité du médicament et des produits de santé, p.18, 2019.

M. Loriot, Dépistage du déficit en dihydropyrimidine déshydrogénase (DPD) et sécurisation des chimiothérapies à base de fluoropyrimidines : mise au point et recommandations nationales du GPCO-Unicancer et du RNPGx, Bulletin du Cancer, vol.105, issue.4, pp.397-407, 2018.

, Des recommandations pour prévenir certaines toxicités sévères des chimiothérapies par fluoropyrimidines, p.13, 2019.

, Chimiothérapies à base de 5-FU ou capécitabine : recherche obligatoire du déficit en DPD avant tout traitement -Point d'Information -ANSM : Agence nationale de sécurité du médicament et des produits de santé, p.13, 2019.

C. A. Lunenburg, Prospective DPYD genotyping to reduce the risk of fluoropyrimidine-induced severe toxicity: Ready for prime time, Eur. J. Cancer, vol.54, pp.40-48, 2016.

S. M. Offer, C. C. Fossum, N. J. Wegner, A. J. Stuflesser, G. L. Butterfield et al.,

. Diasio, Comparative functional analysis of DPYD variants of potential clinical relevance to dihydropyrimidine dehydrogenase activity, Cancer Res, vol.74, issue.9, pp.2545-2554, 2014.

H. Zhang, Y. Li, H. Zhang, and X. Jin, DPYD*5 gene mutation contributes to the reduced DPYD enzyme activity and chemotherapeutic toxicity of 5-FU: results from genotyping study on 75 gastric carcinoma and colon carcinoma patients, Med. Oncol, vol.24, issue.2, pp.251-258, 2007.

M. W. Saif, H. Ezzeldin, K. Vance, S. Sellers, and R. B. Diasio, DPYD*2A mutation: the most common mutation associated with DPD deficiency, Cancer Chemother. Pharmacol, vol.60, issue.4, pp.503-507, 2007.

U. Amstutz, T. K. Froehlich, and C. R. Largiadèr, Dihydropyrimidine dehydrogenase gene as a major predictor of severe 5-fluorouracil toxicity, Pharmacogenomics, vol.12, issue.9, pp.1321-1336, 2011.

A. Uzunkoy, F. Dilmec, A. Ozgonul, A. B. Van-kuilenburg, and F. Akkafa, Investigation of IVS14+ 1G > A polymorphism of DPYD gene in a group of Turkish patients with colorectal cancer, Anticancer Res, vol.27, issue.6B, pp.3899-3902, 2007.

K. Seck, Analysis of the DPYD gene implicated in 5-fluorouracil catabolism in a cohort of Caucasian individuals, Clin. Cancer Res, vol.11, issue.16, pp.5886-5892, 2005.

A. Ofverholm, E. Arkblad, S. Skrtic, P. Albertsson, E. Shubbar et al., Two cases of 5-fluorouracil toxicity linked with gene variants in the DPYD gene, Clin. Biochem, vol.43, issue.3, pp.331-334, 2010.

R. and B. Fredj, Mutational spectrum of dihydropyrimidine dehydrogenase gene (DPYD) in the Tunisian population, C. R. Biol, vol.330, issue.10, pp.764-769, 2007.

A. M. Lee, DPYD variants as predictors of 5-fluorouracil toxicity in adjuvant colon cancer treatment (NCCTG N0147), J. Natl. Cancer Inst, vol.106, issue.12, 2014.

M. W. Saif, Dihydropyrimidine dehydrogenase gene (DPYD) polymorphism among

, Caucasian and non-Caucasian patients with 5-FU-and capecitabine-related toxicity using full sequencing of DPYD, Cancer Genomics Proteomics, vol.10, issue.2, pp.89-92, 2013.

Z. , Influence of dihydropyrimidine dehydrogenase gene (DPYD) coding sequence variants on the development of fluoropyrimidine-related toxicity in patients with high-grade toxicity and patients with excellent tolerance of fluoropyrimidine-based chemotherapy, Neoplasma, vol.56, issue.4, pp.303-316, 2009.

D. Rosmarin, Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis, J. Clin. Oncol, vol.32, issue.10, pp.1031-1039, 2014.

S. Terrazzino, S. Cargnin, M. Del-re, R. Danesi, P. L. Canonico et al.,

. Genazzani, DPYD IVS14+1G>A and 2846A>T genotyping for the prediction of severe fluoropyrimidine-related toxicity: a meta-analysis, Pharmacogenomics, vol.14, issue.11, pp.1255-1272, 2013.

D. Meulendijks, Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data, Lancet Oncol, vol.16, issue.16, pp.1639-1650, 2015.

A. Takabayashi, Dihydropyrimidine dehydrogenase activity and mRNA expression in advanced gastric cancer analyzed in relation to effectiveness of preoperative 5-fluorouracil-based chemotherapy, Int. J. Oncol, vol.17, issue.5, pp.889-895, 2000.

Z. Lu, R. Zhang, and R. B. Diasio, Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy, Cancer Res, vol.53, issue.22, pp.5433-5438, 1993.

M. W. Saif, L. Mattison, T. Carollo, H. Ezzeldin, and R. B. Diasio, Dihydropyrimidine dehydrogenase deficiency in an Indian population, Cancer Chemother. Pharmacol, vol.58, issue.3, pp.396-401, 2006.

G. Milano and M. C. Etienne, Potential importance of dihydropyrimidine dehydrogenase (DPD) in cancer chemotherapy, Pharmacogenetics, vol.4, issue.6, pp.301-306, 1994.

G. Milano and M. C. Etienne, Individualizing therapy with 5-fluorouracil related to dihydropyrimidine dehydrogenase: theory and limits, Ther Drug Monit, vol.18, issue.4, pp.335-340, 1996.

M. C. Van-staveren, Evaluation of an oral uracil loading test to identify DPDdeficient patients using a limited sampling strategy, Br J Clin Pharmacol, vol.81, issue.3, pp.553-561, 2016.

A. F. Galarza, Endogenous plasma and salivary uracil to dihydrouracil ratios and DPYD genotyping as predictors of severe fluoropyrimidine toxicity in patients with gastrointestinal malignancies, Clin. Biochem, vol.49, pp.1221-1226, 2016.

J. Ciccolini, A rapid and inexpensive method for anticipating severe toxicity to fluorouracil and fluorouracil-based chemotherapy, Ther Drug Monit, vol.28, issue.5, pp.678-685, 2006.

F. Coudoré, Validation of an ultra-high performance liquid chromatography tandem mass spectrometric method for quantifying uracil and 5,6-dihydrouracil in human plasma, J Chromatogr Sci, vol.50, issue.10, pp.877-884, 2012.

R. Déporte-féty, High-performance liquid chromatographic assay with ultraviolet detection for quantification of dihydrofluorouracil in human lymphocytes: application to measurement of dihydropyrimidine dehydrogenase activity, J. Chromatogr. B Biomed. Sci. Appl, vol.762, issue.2, pp.203-209, 2001.

E. Gamelin, Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer: A potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosage, J. Clin. Oncol, vol.17, issue.4, p.1105, 1999.

M. B. Garg, J. C. Sevester, J. A. Sakoff, and S. P. Ackland, Simple liquid chromatographic method for the determination of uracil and dihydrouracil plasma levels: a potential pretreatment predictor of 5-fluorouracil toxicity, J. Chromatogr. B Analyt. Technol

. Biomed, Life Sci, vol.774, issue.2, pp.223-230, 2002.

G. F. Cunha-junior, C-uracil breath test to predict 5-fluorouracil toxicity in gastrointestinal cancer patients, Cancer Chemother. Pharmacol, vol.72, issue.13, pp.1273-1282, 2013.

, Bioanalytical method validation, European Medicines Agency

, BiostaTGV -Statistiques en ligne, p.18, 2019.